GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.55 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

45 46 Next >

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

7 Consumer Stocks to Sell Before They Die ↗

September 28, 2022

These are the top consumer stocks to sell before things get worse. These companies are struggling with issues that will take years to fix.

Via InvestorPlace

2 High Yielders Decimated By The Russia-Ukraine War: Is Now The Time To Buy? ↗

September 27, 2022

As the Russia-Ukraine war moves forward, the European economy remains in a fragile state.

Via Benzinga

September 26, 2022

Bloomberg

Via Benzinga

Unilever CEO Alan Jope To Retire Next Year ↗

September 26, 2022

Via Benzinga

AnaptysBio Sells Royalty Interest In Cancer Drug For $45M ↗

September 12, 2022

Via Benzinga

Burberry Finance Chief Joins GSK As First Woman CFO ↗

September 26, 2022

Via Benzinga

7 Stocks to Buy That Can Soar in Good Times or in Bad ↗

September 22, 2022

Investors looking for growth stocks to buy that are largely immune from broader economic woes have come to the right place.

Via InvestorPlace

Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr

September 22, 2022

Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and

Via Spotlight Growth

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement ↗

September 22, 2022

Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK).

Via InvestorPlace

SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK ↗

September 07, 2022

Via Benzinga

Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More.. ↗

September 22, 2022

Reuters

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

September 22, 2022

It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement.

Via InvestorPlace

Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic ↗

September 22, 2022

GSK Plc (NASDAQ: GSK) has entered into an exclusive license agreement for Spero Therapeutics Inc's (NASDAQ: SPRO) late-stage antibiotic asset, tebipenem HBr.

Via Benzinga

Jim Cramer Says This Stock Is A 'Great Spec And I Usually Don't Say That,' And Analysts Approve ↗

September 21, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Certara, Inc. (NASDAQ: CERT) is not bad and also not losing money. "I think it’s a great spec, and I usually don’t say that," he added.

Via Benzinga

3 Biotech Stocks to Buy Now for Extraordinary Gains ↗

September 20, 2022

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

Via InvestorPlace

Haleon Clocks Double Digit Growth In Interim Revenue, Profits; Sticks To Annual Guidance ↗

September 20, 2022

Via Benzinga

Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer ↗

September 20, 2022

Via Benzinga

Recent Stock Purchase September 2022 ↗

September 19, 2022

I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines.

Via Talk Markets

Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗

September 19, 2022

Via Benzinga

WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗

September 16, 2022

Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.

Via Benzinga

Pfizer's Pentavalent Meningococcal Vaccine Candidate Shows Efficacy In Adolescents ↗

September 15, 2022

Via Benzinga

September 2022 Stock Considerations ↗

September 08, 2022

Let’s take a look at my September stock considerations which are similar to recent considerations from one to four months ago.

Via Talk Markets

Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report ↗

September 06, 2022

Via Benzinga

White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox ↗

September 02, 2022

Via Benzinga

Novartis Appoints Merck Executive As Research Head ↗

September 01, 2022

Via Benzinga

With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗

August 30, 2022

Via Benzinga

IDEAYA Achieves First Milestone In GSK Pact For Pol Theta Helicase Inhibitor Candidate ↗

August 29, 2022

Via Benzinga

Is Sanofi A Buy, Despite Recent Stumbles?

August 19, 2022

Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.

Via MarketBeat

Topics Intellectual Property

Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation ↗

August 18, 2022

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.